AND019 is a SERD. Upon oral administration, AND019 specifically targets and binds to ER and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells. Below is a diagram showing AND019’s MOA.
